WO2016159203A1 - ヘムタンパク質の保存液及びヘムタンパク質の安定化方法 - Google Patents
ヘムタンパク質の保存液及びヘムタンパク質の安定化方法 Download PDFInfo
- Publication number
- WO2016159203A1 WO2016159203A1 PCT/JP2016/060597 JP2016060597W WO2016159203A1 WO 2016159203 A1 WO2016159203 A1 WO 2016159203A1 JP 2016060597 W JP2016060597 W JP 2016060597W WO 2016159203 A1 WO2016159203 A1 WO 2016159203A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- heme protein
- acid
- salt
- disulfonic acid
- hemoglobin
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
- G01N21/82—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a precipitate or turbidity
- G01N2021/825—Agglutination
Definitions
- the present invention relates to a hemoprotein storage solution and a hemoprotein stabilization method.
- the present invention relates to a hemoprotein storage solution and a hemoprotein stabilization method useful in immunoassays.
- fecal occult blood tests for detecting blood in feces are widely performed as a primary test for colorectal cancer screening and a screening method for lower gastrointestinal diseases.
- the fecal occult blood test is performed by a chemical measurement method based on a chemical color reaction using the peroxidase-like activity of hemoglobin, a hemoprotein, or by an immunological measurement method using an antibody specific for human hemoglobin,
- immunological measurement methods do not require pre-test dietary restrictions or medication restrictions compared to chemical measurement methods, and can be measured easily and quickly. It has become established.
- hemoglobin is very unstable in solution and easily denatured or decomposed. This denaturation or degradation destroys the three-dimensional structure of hemoglobin and reduces its antigenicity, leading to erroneous measurement results in the immunoassay for hemoglobin.
- the causes of degeneration or degradation of hemoglobin include various things such as increased storage temperature, time, bacteria and enzymes. For example, hemoglobin in solution is relatively stable when frozen or refrigerated. However, it is known that denaturation or decomposition proceeds at room temperature or higher.
- fecal occult blood tests the subject himself collects feces at home, etc., often suspends feces in a sealed container containing a diluent for fecal samples, and in this case, human hemoglobin in the feces is In some cases, the solution is left in a solution for several days and placed under a high temperature by using a transportation means such as a mail. Furthermore, since many specimens and other items are inspected at hospitals and laboratories, it may take a long time to obtain measurement results. Therefore, in the fecal occult blood test, causes such as temperature rise and time lapse overlap, and hemoglobin is likely to be denatured or decomposed.
- a standard sample containing a known concentration of hemoglobin and a control sample containing a known concentration of hemoglobin are used regularly. Calibration and quality control are performed. In calibration, a standard sample containing a plurality of substances to be measured with known concentrations is measured with an automatic analyzer, a calibration curve is created, and the automatic analyzer is calibrated. The control sample is measured with an automatic analyzer, and the analysis accuracy is determined based on whether or not the measured value is within a predetermined range. However, if the hemoglobin contained in the standard sample and the control sample is denatured or decomposed, calibration and accuracy management cannot be performed accurately, resulting in measurement errors.
- a method of adding an antibacterial agent such as thimerosal or chlorhexidine for example, see Patent Document 1
- a method of adding non-human animal hemoglobin for example, see Patent Document 2
- a method of adding non-human animal serum for example, Patent Document 3
- a method of adding a glycosidase-type lytic enzyme see, for example, Patent Document 4
- a method of adding sulfite, disulfite, or the like see, for example, Patent Document 5
- an acylarginine ester an cationic surfactant.
- a method of adding an agent for example, see Patent Document 6
- a method of adding glyoxylic acid for example, see Patent Document 7
- the like have been proposed.
- the present applicant has added a method of adding a water-soluble transition metal complex such as a ferrocyan compound (see, for example, Patent Document 8 and Patent Document 9), and a method of adding an enzymatic degradation product of hemoglobin (see, for example, Patent Document 10).
- a method of adding transition metals for example, see Patent Document 11
- a method of adding an organic acid such as malic acid
- a method of adding defatted albumin for example, see Patent Document 13
- a method of adding iminocarboxylic acid for example, see Patent Document 14
- hemoglobin is very unstable, there is a problem that even these methods for stabilizing hemoglobin have not sufficiently prevented its denaturation or decomposition.
- an object of the present invention is to provide a new hemoprotein preservation solution and a method for stabilizing a hemoprotein, which are effective for denaturation or degradation of hemoprotein represented by hemoglobin.
- the heme protein preservation solution of the present invention contains disulfonic acid or a salt thereof.
- the method for stabilizing a hemoprotein of the present invention is characterized in that disulfonic acid or a salt thereof is allowed to coexist in a sample containing the hemoprotein.
- the present invention includes the following.
- Heme protein preservation solution containing disulfonic acid or a salt thereof.
- the disulfonic acid or a salt thereof is a disulfonic acid or a salt thereof having at least one of a chain hydrocarbon group or a cyclic hydrocarbon group
- the chain hydrocarbon group is a branched or straight chain hydrocarbon group, and the main chain of the branched chain hydrocarbon group or the carbon number of the straight chain hydrocarbon group Disulfonic acid or a salt thereof, wherein A disulfonic acid or a salt thereof, wherein the cyclic hydrocarbon group is a cycloalkylene group or an aryl group, and the cyclic hydrocarbon group has any of 3 to 10 carbon atoms, and
- Disulfonic acid or a salt thereof is composed of methanedisulfonic acid, ethanedisulfonic acid, propanedisulfonic acid, butanedisulfonic acid, naphthalenedisulfonic acid, piperazine-N, N′-bis (2-ethanesulfonic acid) or a salt thereof.
- hemoprotein preservation solution according to any one of (1) to (4), further comprising N- (2-hydroxyethyl) piperazine-N′-ethanesulfonic acid.
- a method for immunoassay of heme protein comprising a step of contacting a heme protein and an anti-heme protein antibody in the presence of disulfonic acid or a salt thereof.
- the hemoprotein can be stably stored while denaturation or degradation of the hemoprotein is suppressed.
- the heme protein preservation solution of the present invention contains disulfonic acid or a salt thereof.
- disulfonic acid or a salt thereof is allowed to coexist in a sample containing the hemoprotein.
- the disulfonic acid or a salt thereof used in the present invention is not particularly limited and can be selected from known ones.
- the disulfonic acid used in the present invention is a disulfonic acid having at least one chain or cyclic hydrocarbon group which may have a saturated or unsaturated bond, and in particular, a chain or cyclic hydrocarbon.
- a disulfonic acid composed of a group and two sulfonic groups is preferred.
- the disulfonic acid used in the present invention may have either a chain hydrocarbon group or a cyclic hydrocarbon group, or may have both.
- the chain hydrocarbon group of the disulfonic acid used in the present invention is a branched or straight chain hydrocarbon group.
- the main chain of the branched hydrocarbon group or the straight chain hydrocarbon group preferably has 1 to 10 carbon atoms, more preferably 1 to 4 carbon atoms, and even more preferably 1 or 2.
- the main chain or straight chain hydrocarbon group of the branched hydrocarbon group is preferably an alkyl group, an alkenyl group, an alkynyl group, an alkylene group, an alkenylene group, or an alkynylene group.
- disulfonic acid having an alkylene group examples include methane disulfonic acid, 1,2-ethanedisulfonic acid (hereinafter referred to as 1,2-EDS), 1,3-propanedisulfonic acid, 1,4-butanedisulfonic acid, 1 , 5-pentanedisulfonic acid, 1,6-hexanedisulfonic acid and the like.
- the cyclic hydrocarbon group of the disulfonic acid used in the present invention preferably has any one of 3 to 10 carbon atoms.
- the cyclic hydrocarbon group is preferably a cycloalkyl group, a cycloalkenyl group, a cycloalkynyl group, or an aryl group.
- the aryl group is preferably a phenylene group or a naphthylene group.
- Examples of the disulfonic acid having a phenylene group or a naphthylene group include 1,2-benzenedisulfonic acid, 1,3-benzenedisulfonic acid, 1,4-benzenedisulfonic acid, 1,6-naphthalenedisulfonic acid, 2,6- And naphthalenedisulfonic acid, 2,7-naphthalenedisulfonic acid, and the like.
- the cyclic hydrocarbon group may be a branched hydrocarbon group.
- the cyclic hydrocarbon group may be substituted with one or more, preferably 1 to 3, more preferably 1 to 2 nitrogen atoms.
- Examples of the disulfonic acid having a hydrocarbon group substituted with a nitrogen atom include piperazine-N, N′-bis (2-ethanesulfonic acid).
- the disulfonic acid used in the present invention is a disulfonic acid in which two sulfone groups are bonded to a chain or cyclic hydrocarbon group.
- the disulfonic acid having a chain hydrocarbon group preferably has two sulfone groups on the main chain of a branched hydrocarbon group or different carbon atoms of a linear hydrocarbon group, more preferably At each of these ends.
- the disulfonic acid used in the present invention is preferably 1,2-ethanedisulfonic acid (1,2-EDS).
- the hydrocarbon group of disulfonic acid used in the present invention may have a substituent such as a halogen group and / or a hydroxy group.
- the branched chain is preferably made of a hydrocarbon.
- the disulfonic acid or its salt used for this invention is at least 1 type, and the mixture which mixed 2 or more types may be sufficient as it.
- the denaturation or degradation of heme protein can be suppressed by including heme protein and disulfonic acid or a salt thereof in the preservation solution or sample.
- the stability of the heme protein can be further enhanced by the fact that the disulfonic acid contains ethanedisulfonic acid.
- the disulfonic acid used in the present invention does not adversely affect the measurement, and is particularly suitable for an immunoassay method using a latex immunoaggregation method.
- the salt of disulfonic acid used in the present invention is not particularly limited, but is a monovalent, divalent, or trivalent metal salt of disulfonic acid.
- the disulfonic acid salt include alkali metal salts, ammonium salts, alkaline earth metal salts, iron salts, and aluminum salts.
- the alkali metal include lithium, sodium, potassium, rubidium, and cesium.
- the alkaline earth metal include calcium, strontium, barium, and radium.
- the upper limit of the concentration of disulfonic acid or a salt thereof contained in the heme protein preservation solution or the sample containing heme protein of the present invention is 0.3 mol / L or less, more preferably 0.2 mol / L or less, and still more preferably 0.8.
- the lower limit is 0.001 mol / L or more, more preferably 0.005 mol / L or more, still more preferably 0.01 mol / L or more, and most preferably 0.02 mol / L or more. If the concentration of disulfonic acid or a salt thereof is less than 0.001 mol / L, the effect of stabilizing the heme protein becomes insufficient. On the other hand, when the concentration of disulfonic acid or a salt thereof exceeds 0.3 mol / L, the immune reaction is inhibited and the measurement tends to be affected, and a sufficient effect of stabilizing the heme protein cannot be obtained.
- the heme protein targeted by the present invention and the heme protein contained in the sample of the present invention can be appropriately selected from proteins containing heme as a constituent component.
- hemoproteins include hemoglobin, myoglobin, peroxidase, or catalase.
- the hemoprotein targeted by the present invention and the hemoprotein contained in the sample of the present invention are preferably hemoproteins to be analyzed immunologically, more preferably human hemoglobin.
- the antigenicity of the hemoprotein can be maintained, so that more accurate measurement of the hemoprotein can be achieved. Become.
- the hemoglobin can include hemoglobin contained in feces, standard samples containing hemoglobin prepared from erythrocytes or hemoglobin marketed as a control, lyophilized hemoglobin, and the like.
- the preservation solution of heme protein or the sample containing heme protein of the present invention may contain a solution capable of dissolving heme protein.
- the solution may be any solution that can dissolve heme protein, and examples thereof include a buffer solution.
- the buffer used for preparing the buffer solution is particularly limited as long as it has a buffer capacity. For example, Good buffer, phosphate buffer, Tris buffer, glycine buffer, borate buffer and the like can be mentioned.
- examples of the good buffer include 2-morpholinoethanesulfonic acid (MES) buffer, bis (2-hydroxyethyl) iminotris (hydroxymethyl) methane (Bis-Tris) buffer, N- (2-acetamide) Iminodiacetic acid (ADA) buffer, piperazine-N, N′-bis (2-ethanesulfonic acid) (PIPES) buffer, N- (2-acetamido) -2-aminoethanesulfonic acid (ACES) buffer, 3-morpholino-2-hydroxypropanesulfonic acid (MOPSO) buffer, N, N-bis (2-hydroxyethyl) -2-aminoethanesulfonic acid (BES) buffer, 3-morpholinopropanesulfonic acid (MOPS) buffer Agent, N- [Tris (hydroxymethyl) methyl] -2-aminoethanesulfonic acid (TES) buffer N- (2-hydroxyethyl) piperazine-N′-ethanes
- the concentration of the buffer is not particularly limited as long as it is a concentration suitable for measurement, but is 0.001 to 2.0 mol / L, preferably 0.005 to 1.5 mol / L, more preferably 0.01 to 1. 0 mol / L.
- the pH of the haem protein preservation solution or the sample containing heme protein of the present invention is preferably in the neutral range, more preferably 5 to 10, and more preferably 6 to 8.
- the pH can be adjusted by a known method, and may be adjusted using NaOH or an appropriate buffer.
- the preservation solution of the hemoprotein or the sample containing the hemoprotein of the present invention is represented by a water-soluble transition metal complex, a ferrocyan compound, an enzymatic degradation product of hemoglobin, a transition metal, an organic acid, an iminocarboxylic acid, albumin or gelatin.
- Known protein protective agents such as inactive proteins and sodium azide.
- an antibacterial agent or the like for preventing unnecessary propagation of microorganisms may be included.
- the stability of heme protein can be enhanced together with the conventional protein protective agent, antibacterial agent and the like without inhibiting the action of the conventional protein protective agent, antibacterial agent and the like.
- albumin from cattle, horses, pigs, sheep, rabbits, humans, rats, etc.
- albumin from cattle, horses, pigs, sheep, rabbits, humans, rats, etc.
- Serum containing may be used.
- concentration of albumin in the stock solution of heme protein of the present invention or the sample containing heme protein is 0.0005 to 2.0 w / v%, more preferably 0.01 to 0.5 w / v%.
- the method for measuring heme protein is not particularly limited, but an immunoassay method using an anti-heme protein antibody (an antibody that specifically binds to heme protein), preferably an anti-human hemoglobin antibody is used. It is an immunological assay. Specifically, in a sample, a hemoprotein (e.g., human hemoglobin) and an anti-hemoprotein antibody (e.g., anti-human hemoglobin antibody) are contacted in the presence of disulfonic acid or a salt thereof to cause an antigen-antibody reaction, Heme protein in the sample is detected or measured based on the formed immune complex.
- an anti-heme protein antibody an antibody that specifically binds to heme protein
- an anti-human hemoglobin antibody preferably an anti-human hemoglobin antibody
- an immunoassay for human hemoglobin is, for example, a method of immunoprecipitation of a sedimentation line by an immunocomplex due to binding of an anti-human hemoglobin antibody and human hemoglobin in a test sample in an agar plate.
- Uniform radial immunodiffusion method to confirm expression latex immunoagglutination method using latex particles sensitized with anti-human hemoglobin antibody, enzyme immunoassay method or radioimmunoassay method using anti-human hemoglobin antibody labeled with enzyme or radioactive element, Gold colloid aggregation colorimetric method using gold colloid particles sensitized with anti-human hemoglobin antibody, immunity between anti-human hemoglobin antibody labeled with metal colloid, etc., and anti-human hemoglobin antibody and human hemoglobin on membrane such as nitrocellulose membrane Immunochromatography using capture antibodies to capture complexes And the like.
- latex immunoaggregation latex particles sensitized with anti-human hemoglobin antibody react with human hemoglobin in a sample, latex particles aggregate due to the formation of immune complexes, and turbidity due to aggregation of the latex Human hemoglobin is measured based on the change in.
- immunochromatography a sample is supplied on a membrane such as a nitrocellulose membrane, and the human hemoglobin in the sample reacts with the anti-human hemoglobin antibody in a labeling reagent holder that holds the anti-human hemoglobin antibody labeled with a metal colloid or the like.
- the immune complex is then moved through the membrane by capillary action, and the immune complex is captured by the capture antibody fixed at a predetermined position on the membrane.
- Human hemoglobin is detected.
- the hemoprotein storage solution of the present invention containing disulfonic acid or a salt thereof or a sample containing heme protein, the antigenic activity of heme protein can be protected and measurement errors can be suppressed. it can.
- the hemoprotein preservation solution of the present invention can be used in various applications as a solution for preserving heme protein, such as a solution for dissolving hemoprotein derived from biological samples such as feces, urine, and blood, It can be used as a solution such as a diluted solution and an extract. In particular, it is useful as a diluent for a stool specimen in a test for detecting heme protein, for example, a fecal occult blood test.
- the heme protein preservation solution of the present invention may contain the above-described heme protein of the present invention, and can be used as various solutions containing the heme protein.
- the method for stabilizing hemoprotein of the present invention can be applied to various samples containing hemoprotein.
- the stock solution of the heme protein of the present invention and the sample containing the heme protein may be a standard sample containing a heme protein or a control sample containing a heme protein, such as a standard containing a heme protein for calibration or quality control of an automatic analyzer. It can be used as a sample or a control sample containing heme protein.
- the standard sample and the control sample containing heme protein are required to have the same measured value of heme protein even when stored for a long period of time.
- the standard sample and the control sample were stored at a relatively high temperature. Even in this case, denaturation or degradation of heme protein in the standard sample and the control sample can be suppressed, which can contribute to stabilization of the measured value of heme protein. Therefore, the stock solution of heme protein of the present invention and the sample containing heme protein are suitable as a standard sample and a control sample containing heme protein.
- the heme protein preservation solution of the present invention can also be provided as a kit for immunological measurement of heme protein (eg, human hemoglobin) used for, for example, fecal occult blood test.
- the kit includes a sample storage container such as a stool collection container, an instruction manual for the kit, and anti-heme when the immunological measurement method is a latex immunoagglutination method, for example. Latex liquid, dilution liquid, etc.
- a detection part including a capture antibody fixed at a predetermined position, and a membrane such as a nitrocellulose film supported on a support.
- Example 1 A pH 7.0 solution containing 0.3 w / v% bovine serum albumin, NaOH, and 0.05 mol / L phosphate buffer as a buffer, with the balance being pure water was prepared. To this solution, 1,2-EDS was added as an additive so as to have each concentration (0.01 to 0.2 mol / L) shown in Table 1 to prepare a solution having each concentration. The hemolyzed hemoglobin was added to 10 mL of each prepared solution so that it might become 600 ng / mL, and it was set as the sample.
- the hemoglobin concentration of each sample was measured (concentration immediately after addition). Each sample was then stored at 37 ° C. The hemoglobin concentration was determined for each sample after storage for 6 hours and after storage for 24 hours (the concentration after storage for 6 hours and the concentration after storage for 24 hours).
- the hemoglobin concentration is measured using an OC sensor DIANA analyzer (manufactured by Eiken Chemical Co., Ltd.) and a dedicated reagent (OC hemodia auto III: Eiken Chemical Co., Ltd.). Specifically, 35 ⁇ L is taken from the sample as a test solution, and in this test solution, latex emulsion (20 vol% anti-human hemoglobin rabbit polyclonal antibody-sensitized latex solution) 60 ⁇ L and diluent (11.92 mg / mL HEPES) 300 ⁇ L And the absorbance was measured at a wavelength of 660 nm. Based on the calibration curve prepared in advance, the hemoglobin concentration in the test solution was determined from the obtained measured value. Each sample was subjected to triple measurement, and the average value of the measurement results was used as the hemoglobin concentration of each sample.
- OC sensor DIANA analyzer manufactured by Eiken Chemical Co., Ltd.
- a dedicated reagent OC hemodia auto III: Eiken Chemical Co., Ltd.
- the residual rate of hemoglobin was determined based on the following formula.
- Residual rate of hemoglobin after storage for 6 hours or 24 hours [%] 100 ⁇ concentration of hemoglobin after storage for 6 hours or concentration after storage for 24 hours [ng / mL] / concentration immediately after addition of control sample [ng / mL] That is, the residual ratio of hemoglobin in each sample is a relative value with the concentration immediately after addition of hemoglobin in the control sample as 100%.
- the control sample in this example was a phosphate buffer (not containing 1,2-EDS) containing bovine serum albumin and NaOH, and the concentration immediately after addition of the control sample was 583 ng / mL. The results are shown in Table 1.
- the sample containing 1,2-EDS which is a disulfonic acid, has a higher residual rate after storage for 6 hours and after storage for 24 hours compared to the control sample, and 1,2-EDS is less than that of hemoglobin. It can be seen that it has a stabilizing effect. Furthermore, it can be seen that with the increase in the concentration of 1,2-EDS, the residual ratio increases, and the effect of stabilizing hemoglobin is enhanced.
- Example 2 0.05 mol / L N- (2-hydroxyethyl) piperazine-N′-ethanesulfonic acid (hereinafter referred to as HEPES) was used in place of the phosphate buffer, and the concentrations shown in Table 2 (0.
- a sample was prepared in the same manner as in Example 1 except that 1,2-EDS was added so that the concentration was 005 to 0.2 mol / L), and the hemoglobin concentration was measured. The results are shown in Table 2.
- the residual ratio of each sample is a relative value in which the concentration immediately after addition (576 ng / mL) in the control sample (HEPES buffer containing bovine serum albumin and NaOH (not including 1,2-EDS) (576 ng / mL) is 100%. Indicated.
- the sample containing 1,2-EDS which is a disulfonic acid, has a higher residual rate after storage for 6 hours and 24 hours than the control sample, and 1,2-EDS is stable for hemoglobin. It can be seen that it has an effect.
- HEPES and 1,2-EDS it can be seen that even in samples having a low concentration of 1,2-EDS of 5 mM, the residual ratio after storage for 6 hours and after storage for 24 hours is high. .
- the residual rate increases with increasing concentration of 1,2-EDS and the effect of stabilizing hemoglobin is enhanced.
- Example 3 instead of phosphate buffer, 0.05 mol / L HEPES, 0.05 mol / L piperazine-N, N′-bis (2-ethanesulfonic acid) (hereinafter referred to as PIPES), or 0.05 mol / L
- PIPES 2-morpholinoethanesulfonic acid
- 1,2-EDS was added to the concentration shown in Table 3.
- the hemoglobin concentration was measured. The results are shown in Table 3.
- the residual rate of each sample is a relative value with the concentration immediately after addition (583 ng / mL) as 100% in the control sample (phosphate buffer containing bovine serum albumin and NaOH (not including 1,2-EDS)). It showed in.
- the sample containing HEPES and 1,2-EDS has a significantly higher residual rate after storage for 6 hours and after storage for 24 hours compared to a sample containing HEPES as a buffer and not containing 1,2-EDS. It was found that the inhibitory effect on hemoglobin denaturation or degradation was extremely high, and that hemoglobin could be stabilized in the long term.
- the sample containing HEPES and 1,2-EDS is stored after 6 hours and after storage for 24 hours, compared with the samples containing PIPES and MES, which are good buffer agents, and 1,2-EDS. From the fact that the residual ratio is high and the effect of suppressing the denaturation or degradation of hemoglobin is further enhanced, it can be seen that it has a synergistic hemoglobin stabilization effect.
- Example 4 In place of 1,2-EDS, 1,4-butanedisulfonic acid (hereinafter referred to as 1,4-BDS) or 2,6-naphthalenedisulfonic acid (hereinafter referred to as 2,6-NDS), PIPES is shown in Table 4.
- the sample was prepared in the same manner as in Example 1 except that 0.05 mol / L HEPES was used instead of the phosphate buffer, and the hemoglobin concentration was measured. did. The results are shown in Table 4.
- the residual rate of each sample was shown by the relative value which makes the concentration (548 ng / mL) immediately after the addition in a control sample (phosphate buffer solution (it does not contain disulfonic acid) containing bovine serum albumin and NaOH) 100%. .
- Comparative Example 1 A point in which 8-anilino-1-naphthalenesulfonic acid (hereinafter referred to as ANS) or sodium 2-mercaptoethanesulfonate (hereinafter referred to as MESS) was added to 0.01 mol / L instead of 1,2-EDS. Except for the above, a sample was prepared in the same manner as in Example 1, and the hemoglobin concentration was measured. The results are shown in Table 5. In addition, the residual rate of each sample was shown by the relative value which makes the concentration (583ng / mL) immediately after the addition in a control sample (the phosphate buffer solution containing bovine serum albumin and NaOH (without additives)) 100% .
- ANS 8-anilino-1-naphthalenesulfonic acid
- MESS sodium 2-mercaptoethanesulfonate
- hemoglobin may be denatured or decomposed.
- the storage solutions and samples containing disulfonic acid such as 1,4-BDS, 2,6-NDS, and 1,2-EDS are stored after 6 hours and stored even at a high temperature of 37 ° C. It was shown that the residual ratio of hemoglobin after storage for 24 hours can be kept high. From this result, it can be seen that the preservation solution and the sample containing the disulfonic acid of the present invention have the effect of stabilizing hemoglobin by suppressing the denaturation or decomposition of hemoglobin even when the temperature rises and time elapses.
- the hemoprotein preservation solution and the hemoprotein stabilization method of the present invention containing disulfonic acid or a salt thereof can stabilize the hemoprotein by suppressing the denaturation or degradation of the hemoprotein.
- the hemoprotein can be stably stored by suppressing the denaturation or degradation of the hemoprotein, and the diluted solution for fecal occult blood test Heme proteins such as standard samples containing heme proteins and control samples containing heme proteins can be stably stored.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
前記鎖式の炭化水素基が分岐状もしくは直鎖状の炭化水素基であり、かつ分岐状の前記鎖式の炭化水素基の主鎖もしくは直鎖状の前記鎖式の炭化水素基の炭素数が1乃至10のいずれかであるジスルホン酸又はその塩、
前記環式の炭化水素基がシクロアルキレン基もしくはアリール基であり、かつ前記環式の炭化水素基の炭素数が3乃至10のいずれかであるジスルホン酸又はその塩、並びに、
前記シクロアルキレン基もしくは前記アリール基が1個以上の置換された窒素原子を有するジスルホン酸又はその塩からなる群より選択される少なくとも1種である(1)に記載のヘムタンパク質の保存液。
0.3w/v%の牛血清アルブミン、NaOH、及び緩衝液として0.05mol/Lのリン酸緩衝液を含み、残部を純水とするpH7.0の溶液を調製した。この溶液に、添加物として1,2-EDSを表1に示す各濃度(0.01乃至0.2mol/L)となるように添加し、各濃度の溶液を調製した。この調製した各溶液10mLに溶血ヘモグロビンを600ng/mLとなるように添加し、試料とした。
すなわち、各試料のヘモグロビンの残存率は、対照試料におけるヘモグロビンの添加直後濃度を100%とする相対値である。本実施例における対照試料は、牛血清アルブミン及びNaOHを含むリン酸緩衝液(1,2-EDSを含まない)であり、対照試料の添加直後濃度は583ng/mLであった。結果を表1に示す。
リン酸緩衝液の代わりに、0.05mol/LのN-(2-ヒドロキシエチル)ピペラジン-N’-エタンスルホン酸(以下、HEPESという)を用いた点、表2に示す各濃度(0.005乃至0.2mol/L)となるように1,2-EDSを添加した点以外は、実施例1と同様にして試料を調製し、ヘモグロビン濃度を測定した。結果を表2に示す。なお、各試料の残存率は、対照試料(牛血清アルブミン及びNaOHを含むHEPES緩衝液(1,2-EDSを含まない))における添加直後濃度(576ng/mL)を100%とする相対値で示した。
リン酸緩衝液の代わりに、0.05mol/LのHEPES、0.05mol/Lのピペラジン-N,N’-ビス(2-エタンスルホン酸)(以下、PIPESという)、又は0.05mol/Lの2-モルホリノエタンスルホン酸(以下、MESという)を用いた点、1,2-EDSを表3に示す濃度となるように添加した点以外は、実施例1と同様にして試料を調製し、ヘモグロビン濃度を測定した。結果を表3に示す。なお、各試料の残存率は、対照試料(牛血清アルブミン及びNaOHを含むリン酸緩衝液(1,2-EDSを含まない))における添加直後濃度(583ng/mL)を100%とする相対値で示した。
1,2-EDSの代わりに、1,4-ブタンジスルホン酸(以下、1,4-BDSという)、又は2,6-ナフタレンジスルホン酸(以下、2,6-NDSという)、PIPESを表4に示す濃度となるように添加した点、及びリン酸緩衝液の代わりに、0.05mol/LのHEPESを用いた点以外は、実施例1と同様にして試料を調製し、ヘモグロビン濃度を測定した。結果を表4に示す。なお、各試料の残存率は、対照試料(牛血清アルブミン及びNaOHを含むリン酸緩衝液(ジスルホン酸を含まない))における添加直後濃度(548ng/mL)を100%とする相対値で示した。
1,2-EDSの代わりに8-アニリノ-1-ナフタレンスルホン酸(以下、ANSという)もしくは2-メルカプトエタンスルホン酸ナトリウム(以下、MESSという)を0.01mol/Lとなるように添加した点以外は、実施例1と同様にして試料を調製し、ヘモグロビン濃度を測定した。結果を表5に示す。なお、各試料の残存率は、対照試料(牛血清アルブミン及びNaOHを含むリン酸緩衝液(添加物を含まない))における添加直後濃度(583ng/mL)を100%とする相対値で示した。
Claims (10)
- ジスルホン酸又はその塩を含むヘムタンパク質の保存液。
- 前記ジスルホン酸又はその塩が、鎖式の炭化水素基又は環式の炭化水素基の少なくとも1つを有するジスルホン酸又はその塩であって、
前記鎖式の炭化水素基が分岐状もしくは直鎖状の炭化水素基であり、かつ分岐状の前記鎖式の炭化水素基の主鎖もしくは直鎖状の前記鎖式の炭化水素基の炭素数が1乃至10のいずれかであるジスルホン酸又はその塩、
前記環式の炭化水素基がシクロアルキレン基もしくはアリール基であり、かつ前記環式の炭化水素基の炭素数が3乃至10のいずれかであるジスルホン酸又はその塩、並びに、
前記シクロアルキレン基もしくは前記アリール基が1個以上の置換された窒素原子を有するジスルホン酸又はその塩からなる群より選択される少なくとも1種である請求項1に記載のヘムタンパク質の保存液。 - 前記ジスルホン酸又はその塩が、メタンジスルホン酸、エタンジスルホン酸、プロパンジスルホン酸、ブタンジスルホン酸、ナフタレンジスルホン酸、ピペラジン-N,N’-ビス(2-エタンスルホン酸)又はその塩からなる群より選択される少なくとも1種である請求項1又は2に記載のヘムタンパク質の保存液。
- 前記ジスルホン酸又はその塩の濃度が0.001mol/L以上0.3mol/L以下である請求項1乃至3のいずれか1項に記載のヘムタンパク質の保存液。
- N-(2-ヒドロキシエチル)ピペラジン-N’-エタンスルホン酸をさらに含む請求項1乃至4のいずれか1項に記載のヘムタンパク質の保存液。
- 標準試料又はコントロール試料として用いられる、ヘムタンパク質をさらに含む請求項1乃至5のいずれか1項に記載のヘムタンパク質の保存液。
- 免疫学的測定に用いられる請求項1乃至6のいずれか1項に記載のヘムタンパク質の保存液。
- ヘムタンパク質を含む試料中に、ジスルホン酸又はその塩を共存させるヘムタンパク質の安定化方法。
- 前記ジスルホン酸又はその塩の濃度が0.001mol/L以上0.3mol/L以下である請求項8記載のヘムタンパク質の安定化方法。
- ヘムタンパク質と抗ヘムタンパク質抗体とをジスルホン酸又はその塩の存在下で接触させる工程を含む、ヘムタンパク質の免疫学的測定方法。
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES16773083T ES2804551T3 (es) | 2015-03-31 | 2016-03-31 | Solución conservante para hemoproteína, y procedimiento de estabilización de hemoproteína |
EP16773083.7A EP3279660B1 (en) | 2015-03-31 | 2016-03-31 | Preservative solution for heme protein, and method for stabilizing heme protein |
CN201680030211.7A CN107615069B (zh) | 2015-03-31 | 2016-03-31 | 血红素蛋白保存液和血红素蛋白稳定化方法 |
AU2016240847A AU2016240847B2 (en) | 2015-03-31 | 2016-03-31 | Preservative solution for heme protein, and method for stabilizing heme protein |
JP2017510166A JP6818675B2 (ja) | 2015-03-31 | 2016-03-31 | ヘムタンパク質の保存液及びヘムタンパク質の安定化方法 |
US15/563,088 US11125659B2 (en) | 2015-03-31 | 2016-03-31 | Preservative solution for heme protein, and method for stabilizing heme protein |
SG11201708762QA SG11201708762QA (en) | 2015-03-31 | 2016-03-31 | Preservative solution for heme protein, and method for stabilizing heme protein |
KR1020177031398A KR102646392B1 (ko) | 2015-03-31 | 2016-03-31 | 헴 단백질의 보존액 및 헴 단백질의 안정화 방법 |
HK18103932.5A HK1244539A1 (zh) | 2015-03-31 | 2018-03-21 | 血紅素蛋白保存液和血紅素蛋白穩定化方法 |
US17/404,715 US20210381935A1 (en) | 2015-03-31 | 2021-08-17 | Preservative solution for heme protein, and method for stabilizing heme protein |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015070667 | 2015-03-31 | ||
JP2015-070667 | 2015-03-31 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/563,088 A-371-Of-International US11125659B2 (en) | 2015-03-31 | 2016-03-31 | Preservative solution for heme protein, and method for stabilizing heme protein |
US17/404,715 Division US20210381935A1 (en) | 2015-03-31 | 2021-08-17 | Preservative solution for heme protein, and method for stabilizing heme protein |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016159203A1 true WO2016159203A1 (ja) | 2016-10-06 |
Family
ID=57007254
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2016/060597 WO2016159203A1 (ja) | 2015-03-31 | 2016-03-31 | ヘムタンパク質の保存液及びヘムタンパク質の安定化方法 |
Country Status (10)
Country | Link |
---|---|
US (2) | US11125659B2 (ja) |
EP (1) | EP3279660B1 (ja) |
JP (1) | JP6818675B2 (ja) |
KR (1) | KR102646392B1 (ja) |
CN (1) | CN107615069B (ja) |
AU (1) | AU2016240847B2 (ja) |
ES (1) | ES2804551T3 (ja) |
HK (1) | HK1244539A1 (ja) |
SG (2) | SG11201708762QA (ja) |
WO (1) | WO2016159203A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112285337A (zh) * | 2020-10-15 | 2021-01-29 | 爱若维生物科技(苏州)有限公司 | 一种兽用血细胞分析仪用鞘液及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000258420A (ja) * | 1999-03-05 | 2000-09-22 | Azwell Inc | 溶液中のヒトヘモグロビンの安定化方法および安定化溶液 |
JP2001249132A (ja) * | 2000-03-06 | 2001-09-14 | Eiken Chem Co Ltd | ヘムタンパク質の安定化方法 |
JP2013257216A (ja) * | 2012-06-13 | 2013-12-26 | Godo Shusei Co Ltd | ヒトヘモグロビンの安定化方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0281251A3 (en) | 1987-02-04 | 1988-09-28 | International Immunoassay Laboratories, Inc. | A method for preparing a fecal sample composition for immunoassay testing |
JP2654181B2 (ja) | 1989-05-10 | 1997-09-17 | 日東電工株式会社 | ヒトヘモグロビンの検出方法 |
US5242832A (en) | 1990-03-01 | 1993-09-07 | Toa Medical Electronics Co., Ltd. | Reagent for measurement of leukocytes and hemoglobin in blood |
JP2902095B2 (ja) | 1990-10-08 | 1999-06-07 | 日東電工株式会社 | ヒトヘモグロビンを含有する被検液の保存方法及びそれに用いる便溶解用緩衝液 |
JP2723713B2 (ja) | 1991-09-11 | 1998-03-09 | 東洋機械金属株式会社 | 射出成形機の制御方法 |
JPH07229902A (ja) | 1994-02-22 | 1995-08-29 | Eiken Chem Co Ltd | ヘモグロビンの安定化方法 |
JPH11118806A (ja) | 1997-10-13 | 1999-04-30 | Eiken Chem Co Ltd | ヘモグロビンの安定化方法 |
JP4039590B2 (ja) | 1998-01-30 | 2008-01-30 | 栄研化学株式会社 | ヘモグロビン試料の安定化 |
CA2330628A1 (en) * | 1998-05-01 | 1999-11-11 | Queen's University At Kingston | Method for diagnosing a vascular condition |
AU783188B2 (en) * | 1999-06-01 | 2005-10-06 | Proteome Sciences Plc | Method and compositions relating to insulin resistance disorders |
JP4502352B2 (ja) | 2001-06-29 | 2010-07-14 | 栄研化学株式会社 | ヘムタンパク質の安定化方法および保存溶液 |
JP3898947B2 (ja) | 2001-12-27 | 2007-03-28 | 栄研化学株式会社 | ヘムタンパク質の安定化方法およびこれに用いる保存溶液 |
AU2003235974A1 (en) * | 2002-06-14 | 2003-12-31 | Arkray, Inc. | Method of assay with sulfonic acid compound and nitro compound |
EP1770399A4 (en) * | 2004-12-03 | 2012-03-14 | Arkray Inc | INSPECTION INSTRUMENT |
CA3005835C (en) * | 2004-12-22 | 2023-01-31 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
JP5017614B2 (ja) * | 2007-02-13 | 2012-09-05 | 株式会社シノテスト | 試料中の測定対象物質の測定方法及び測定試薬、非特異的発色を抑制する方法、並びに非特異的発色抑制剤 |
JP5422108B2 (ja) * | 2007-10-16 | 2014-02-19 | 栄研化学株式会社 | ヘムタンパク質の安定化方法及び保存溶液 |
CN101795680A (zh) * | 2007-11-16 | 2010-08-04 | 波苏蛋白试剂公司 | 稳定蛋白质的辅剂 |
JP2009222710A (ja) | 2008-02-19 | 2009-10-01 | Sanyo Chem Ind Ltd | ヘモグロビン安定化剤及びヘモグロビンの安定化方法 |
-
2016
- 2016-03-31 SG SG11201708762QA patent/SG11201708762QA/en unknown
- 2016-03-31 JP JP2017510166A patent/JP6818675B2/ja active Active
- 2016-03-31 WO PCT/JP2016/060597 patent/WO2016159203A1/ja active Application Filing
- 2016-03-31 US US15/563,088 patent/US11125659B2/en active Active
- 2016-03-31 KR KR1020177031398A patent/KR102646392B1/ko active IP Right Grant
- 2016-03-31 ES ES16773083T patent/ES2804551T3/es active Active
- 2016-03-31 CN CN201680030211.7A patent/CN107615069B/zh active Active
- 2016-03-31 EP EP16773083.7A patent/EP3279660B1/en active Active
- 2016-03-31 SG SG10201909108W patent/SG10201909108WA/en unknown
- 2016-03-31 AU AU2016240847A patent/AU2016240847B2/en active Active
-
2018
- 2018-03-21 HK HK18103932.5A patent/HK1244539A1/zh unknown
-
2021
- 2021-08-17 US US17/404,715 patent/US20210381935A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000258420A (ja) * | 1999-03-05 | 2000-09-22 | Azwell Inc | 溶液中のヒトヘモグロビンの安定化方法および安定化溶液 |
JP2001249132A (ja) * | 2000-03-06 | 2001-09-14 | Eiken Chem Co Ltd | ヘムタンパク質の安定化方法 |
JP2013257216A (ja) * | 2012-06-13 | 2013-12-26 | Godo Shusei Co Ltd | ヒトヘモグロビンの安定化方法 |
Non-Patent Citations (1)
Title |
---|
See also references of EP3279660A4 * |
Also Published As
Publication number | Publication date |
---|---|
SG10201909108WA (en) | 2019-11-28 |
KR20170132845A (ko) | 2017-12-04 |
US11125659B2 (en) | 2021-09-21 |
AU2016240847B2 (en) | 2021-07-29 |
CN107615069B (zh) | 2021-04-20 |
AU2016240847A1 (en) | 2017-11-09 |
SG11201708762QA (en) | 2017-11-29 |
JPWO2016159203A1 (ja) | 2018-02-01 |
CN107615069A (zh) | 2018-01-19 |
EP3279660B1 (en) | 2020-04-29 |
ES2804551T3 (es) | 2021-02-08 |
US20180172562A1 (en) | 2018-06-21 |
EP3279660A4 (en) | 2018-09-05 |
HK1244539A1 (zh) | 2018-08-10 |
US20210381935A1 (en) | 2021-12-09 |
EP3279660A1 (en) | 2018-02-07 |
KR102646392B1 (ko) | 2024-03-11 |
JP6818675B2 (ja) | 2021-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2204648B1 (en) | Method of stabilizing hem protein and storage solution therefor | |
CN109633148B (zh) | Kl-6检测乳胶凝集试剂 | |
JP6434843B2 (ja) | ヘムタンパク質の保存液及びヘムタンパク質の安定化方法 | |
US9046517B2 (en) | Cystatin C adsorption inhibitor | |
US20210381935A1 (en) | Preservative solution for heme protein, and method for stabilizing heme protein | |
JP2022033286A (ja) | ヘモグロビンの測定試薬、測定キット及び測定方法 | |
KR20030022314A (ko) | 불용성담체입자를 사용하는 면역측정방법 및 그 시약 | |
JP7325334B2 (ja) | ヘモグロビンとハプトグロビンとの複合体を安定化する方法、及びヘモグロビンを含む検体を保存するための保存溶液 | |
KR102181485B1 (ko) | 면역학적 측정 방법 및 측정 시약 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16773083 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017510166 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2016773083 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11201708762Q Country of ref document: SG |
|
ENP | Entry into the national phase |
Ref document number: 20177031398 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2016240847 Country of ref document: AU Date of ref document: 20160331 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15563088 Country of ref document: US |